AKUMS Akums Drugs Q2 FY27 results (Jul–Sep 2026) and concall
Akums had a strong Q2 FY27, led by its CDMO business: CDMO volumes grew more than 20% and revenue rose 38.6% YoY, taking consolidated revenue to ₹1,342 crores (+31.9% YoY) and EBITDA to ₹195 crores (+106% YoY). Margins expanded sharply YoY to 14.5% but slipped from 15% in Q1 FY27, because CDMO EBITDA lagged CDMO revenue growth sequentially. Its export projects moved forward: Zambia purchase orders are in hand for Q1 FY28 revenue, a European dossier has been filed with supplies due in FY28, and a second Baddi plant is being commissioned. The API business is still loss-making and domestic brande
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 1700.0%, net profit up 167.4% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -7 | 12 | 0 | -2 | 15 +314% | 10 −17% | 14 | 32 +1700% |
| EBITDA | 121 | 94 | 129 | 94 | 147 +21% | 152 +62% | 175 +36% | 195 +107% |
| Net profit | 66 | 150 | 65 | 43 | 68 +3% | 81 −46% | 101 +55% | 115 +167% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
